Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 UpdateEli Muchtar, Taimur Sher, Angela Dispenzieri et al.|Mayo Clinic Proceedings|2021Cited by 86
Enhancing the R‐ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cellsWilson I. Gonsalves, Shaji Kumar, Miriam Hobbs et al.|American Journal of Hematology|2019Cited by 63
Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk CytogeneticsRajshekhar Chakraborty, Morie A. Gertz, Eli Muchtar et al.|Transplantation and Cellular Therapy|2017Cited by 57
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myelomaSaurabh Zanwar, Shaji Kumar, Matthew Ho et al.|American Journal of Hematology|2023Cited by 56
The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatmentEli Muchtar, Morie A. Gertz, Dragan Jevremović et al.|Blood|2016Cited by 56